JP4852223B2 - Coaggregation inhibitor of oral bacteria - Google Patents

Coaggregation inhibitor of oral bacteria Download PDF

Info

Publication number
JP4852223B2
JP4852223B2 JP2003175914A JP2003175914A JP4852223B2 JP 4852223 B2 JP4852223 B2 JP 4852223B2 JP 2003175914 A JP2003175914 A JP 2003175914A JP 2003175914 A JP2003175914 A JP 2003175914A JP 4852223 B2 JP4852223 B2 JP 4852223B2
Authority
JP
Japan
Prior art keywords
erythritol
bacteria
coaggregation
plaque
oral
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP2003175914A
Other languages
Japanese (ja)
Other versions
JP2005008579A (en
Inventor
和彦 加藤
義高 矢納
滋人 茅根
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kao Corp
Original Assignee
Kao Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kao Corp filed Critical Kao Corp
Priority to JP2003175914A priority Critical patent/JP4852223B2/en
Publication of JP2005008579A publication Critical patent/JP2005008579A/en
Application granted granted Critical
Publication of JP4852223B2 publication Critical patent/JP4852223B2/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Description

【0001】
【発明の属する技術分野】
本発明は、歯垢の形成に関係する口腔細菌の共凝集を抑制し、虫歯や歯周病の予防効果に優れる口腔細菌の共凝集抑制剤、口腔用組成物等に関する。
【0002】
【従来の技術】
歯垢は、歯の表面に付着したネバネバした細菌の塊である。この歯垢の形成は、歯牙表面における唾液成分よりなるペリクル(獲得被膜)の形成により始まる。ペリクルは、歯牙表面に形成された不定形の膜様の構造物であり、糖タンパク質、ポリペプタイド等の唾液成分が歯牙表面に選択的に吸着されたものであるとされている。次に、ペリクル表面にアクチノマイセス・ビスコーサス(Actinomyces viscosus)等の細菌が付着し、さらに、この付着細菌を介して、様々な細菌の付着が起こり、これらの細菌が繁殖して歯垢が形成される。
【0003】
これら細菌と細菌との間の付着が共凝集というものであり、この共凝集によって、ペリクルと強い結合力を持たない細菌でも、歯垢中への定着が可能になるとされている。例えば、虫歯や歯周病の原因とされるstreptococcus mutansやporphyromonas gingivalisは、直接的にペリクルと結合力を持たないが、この共凝集によって歯垢へ定着し、虫歯や歯周病を誘発する原因の一つになるとされている。
【0004】
このように形成された歯垢は、歯と歯の間や歯と歯肉の境目で厚くなり沈積する。歯垢中には、細菌によって産生された酸や毒素、組織を破壊する酵素等が存在するため、虫歯や歯肉炎、歯周炎等の主な原因の一つになる。従って、歯垢の形成を抑制すること、すでに形成されてしまった歯垢を完全に取り除くことは、虫歯の予防・治療、歯周疾患の予防・治療において非常に有効な手段である。
【0005】
このような歯垢の形成を抑制する手段として、殺菌剤が広く利用されてきた。しかし、この殺菌剤を口腔内に適用する場合、口腔細菌の殺菌効果だけでなく口腔粘膜への影響も考慮する必要があるため、その配合濃度は低くせざるを得ない。このような配合濃度は、歯垢の形成を抑制するための効果が決して十分とはいえなかった。
【0006】
また、形成されてしまった歯垢を、研磨剤を含む歯磨きでブラッシングする方法も広く利用されているが、ブラッシングだけで歯垢を完全に取り除くことは難しく、磨き残してしまった歯垢が、虫歯や歯肉炎、歯周炎を引き起こす原因となってしまう。したがって、従来の手段を用いて歯垢の除去をするだけでは、虫歯や歯周病の予防効果は未だ不十分といえる。
【0007】
一方、エリスリトールは、主に食品の甘味料に使用される糖アルコールの1種である。特許文献1には、エリスリトールの抗う触性、すなわち、通常存在するう触性の甘味剤の一部をエリスリトールで置換することによって、通常のう触性の甘味剤が存在するにもかかわらず、過剰な酸の生成を伴わないことが開示されている。これは、エリスリトールが、口中のバクテリア、特に連鎖球菌によっては発酵されず、つまり、細菌自身がエリスリトールを代謝することができないため、虫歯の原因である乳酸を生成せず、また、歯垢を形成する水不溶性グルカンを生成しないという性質によるものである。
【0008】
虫歯や歯周病の原因となる病原細菌の歯垢への定着、繁殖を防ぐためには、細菌と細菌の共凝集を抑制することが有効である。特許文献2には、アミノ糖を抗歯垢剤として含む口腔衛生組成物が開示され、N−ヘプチルガラクトシルアミン、N−ヘプチルラクトシルアミン、N−デシルラクトシルアミン等のアミノ糖が細菌凝集の阻害活性を示すことが開示されている。しかしながら、これらアミノ糖は、組成物中での保存安定性が悪く、また、コストも高いという問題があった。
【0009】
【特許文献1】
特開平10−33138号
【特許文献2】
特開平6−24948号
【0010】
【発明が解決しようとする課題】
本発明の目的は、口腔細菌の共凝集を抑制して、虫歯や歯周病の原因である歯垢の形成を抑え、虫歯や歯周病の予防効果に優れた口腔細菌の共凝集抑制剤を提供することを目的とする。
【0011】
【課題を解決するための手段】
本発明は、エリスリトールを含む歯周病原因細菌の共凝集抑制剤である。本発明に係る歯周病原因細菌の共凝集抑制剤を口腔に適用することによって、歯周病原因細菌の共凝集を効果的に抑制することが可能である。
【0012】
口腔細菌の共凝集には、菌種に固有の特異的なアドヘジン、及び結合レセプターが関与しており、特定の菌種間でのみ共凝集が起こるとされている。エリスリトールが口腔細菌の共凝集を効果的に抑えるメカニズムは未だ明快ではないが、細菌と細菌の共凝集を起こす前に、エリスリトールが細菌と細菌の共凝集を引き起こすレセプターに作用することにより、細菌の共凝集を阻止することを可能にしたためであると推定している。
【0013】
【発明の実施の形態】
ここで、エリスリトールの構造としては、L−エリスリトール、D−エリスリトール、meso−エリスリトールの3種の異性体が存在するが、本発明はこれらいずれの構造のものであってもよい。本発明において使用されるエリスリトールとしては、ブドウ糖を発酵させて製造したものが主として用いられ、日研化学(株)、三菱化学フーズ(株)社製等のものが使用できる。
【0014】
エリスリトールの配合量は、十分な口腔細菌の共凝集抑制効果および保存安定性の観点から、0.1〜80質量%、好ましくは、1〜60質量%であり、特に10〜50質量%であることが好ましい。
【0015】
本発明の口腔用組成物には、前記成分の他、例えば発泡剤、発泡助剤、研磨剤、湿潤剤、粘結剤、増量剤、甘味剤、保存料、殺菌剤、薬効成分、粘着剤、顔料、色素、香料等を適宜含有させることができる。
本発明の口腔用組成物等は、例えば溶液状、ゲル状、ペースト状といった剤形に調製されることができる。また、本発明に係る共凝集抑制剤は、歯磨き剤、液体歯磨き剤、洗口液等の口腔用組成物に用いることができ、或いは、キャンディーやチューインガムに用いることもできる。
【0016】
また、エリスリトールを含む本発明品に、さらにアミノ酸を併用することで、口腔細菌の共凝集抑制効果を高めることができる。これは、エリスリトールと同様に、細菌と細菌の共凝集を起こす前に、エリスリトールが細菌と細菌の共凝集を引き起こすレセプターに作用することにより、細菌の共凝集を阻止することを可能にしたためであると推定している。
【0017】
ここでのアミノ酸は、リジン、アルギニン、ヒスチジン、トリプトファン、プロリン、オキシプロリン等の塩基性アミノ酸が好ましく、コストや保存安定性の観点から、リジン、アルギニンがより好ましい。
【0018】
アミノ酸の配合量は、十分な口腔細菌の共凝集抑制効果および保存安定性の観点から、0.01〜10質量%、好ましくは、0.05〜5質量%であり、特に0.1〜2質量%であることが好ましい。
【0019】
また、エリスリトール、又はエリスリトール及びアミノ酸を含む本発明品に、さらにアルギン酸ナトリウムを併用することで、エリスリトールの口腔への残留性を高めることができる。これは、アルギン酸ナトリウムがカルシウムイオンと反応してゲルを生成する性質によるものと推定している。生成したアルギン酸カルシウムゲル内に、エリスリトールが取り込まれやすくなり、さらに、このゲルが歯や粘膜へ吸着することによって、口腔への残留性が高まるものであり、また、この時、カルシウムイオンは主にだ液中から供給されるものと推定している。
【0020】
この場合、エリスリトールとアルギン酸ナトリウムの配合比(質量比)は50:1〜250:1、特に、100:1〜200:1であることが好ましい。
ここでのアルギン酸ナトリウムは、アルギン酸を構成するマニュロン酸とグルロン酸の比率に影響を受けないが、(株)キミカ、大日本製薬社製等から市販され、容易に入手可能な分子内マニュロン酸/グルロン酸(M/G比)が0.5〜2.5のものが使用可能である。
【0021】
【実施例】
以下、実験例及び実施例を示し、本発明をより具体的に説明するが、これらのものは本発明の範囲を限定するものではない。
【0022】
<実施例A>口腔細菌の共凝集抑制効果
ポルフィロモナス・ジンジバリス(porphyromonas gingivalis) 、アクチノマイセス・ビスコサス(Actinomices viscoccus)、フゾバクテリウム・ヌクレタム(Fusobacterium nucleatum)の3種の口腔内細菌(各約106個ずつ)を試験管に加え、生理食塩水を20ml加えて細菌を十分に分散した。さらに、前記細菌が十分に分散させた試験管にそれぞれグリセリン、エリスリトール、キシリトール、ソルビトールを加え、水溶液の濃度が1.0質量%となるように調製した。この水溶液を4℃で静置し、30分間放置後の溶液の沈殿の有無について目視観察した。結果を表1に示した。
【0023】
【表1】

Figure 0004852223
【0024】
<判断基準>
全く白色の沈殿物を認めない : ○
わずかに白色の沈殿物を認める : △
明かな白色の沈殿物を認める : ×
【0025】
<実施例B>エリスリトールの口腔における残留性
人から採取しただ液の中に、ハイドロキシアパタイトペレット(旭光学社製、10mm×10mm、以下HAPという。)を加え、37℃で1時間撹拌し、だ液コートHAPを調製した。表2に示した試験溶液A、B、C、D、E、F、G、Hに、このだ液コートHAPを浸漬して2分間撹拌した後、だ液コートHAPを取り出した。ここに、アセトニトリル/水(80/20)の混合溶液2mlを加え、十分撹拌した後、0.45μmのミリポアフィルターでろ過した。ろ液は下記の条件で液体クロマトグラフ分析し、エリスリトールを定量した。結果を表3に示した。
【0026】
【表2】
Figure 0004852223
【0027】
【表3】
Figure 0004852223
【0028】
<条件>
分析カラム :東ソー社製TSK-GEL Amido-80(4.6mm×250mm)
溶離液 :アセトニトリル/水(80/20)
流速 :1mL/分
カラム温度 :40℃
検出器 :示差屈折計
注入量 :20μL
【0029】
<実施例C>歯垢の形成抑制効果
歯科衛生士による歯科清掃により、被験者10名の歯垢を完全に取り除いた、後、被験者は後述の実施例において示された組成物を各々2週間ずつ使用した。その後、24時間実施例において示された組成物の使用を中止し、24時間後、歯科衛生士がSilness and LoeのPI(Plaque Index)を用いて、歯垢の形成量を測定した。結果を表4に示した。ただし、結果は被験者10名の平均値で示した。また、実施例において示された組成物は、以下の方法で使用した。
【0030】
<使用方法>
1.練り歯磨き、液状歯磨き:歯磨き約1gをハブラシに付けて、約2分間ブラッシングし、1日3回使用した。
2.洗口液:洗口液約10mlを口に含み、約30秒間含嗽した。毎食後、さらに、食間に使用し、1日6回使用した。
3.キャンディー:キャンディー約5gを口に含み、噛まずになめた。毎食後、さらに、食間に使用し、1日6回使用した。
4.チューインガム:チューインガム約3gを口に含み、約10分間かんだ。毎食後、さらに、食間に使用し、1日6回使用した。
【0031】
<判断基準>
PI=0〜20%未満 : ◎(高い抑制効果を認める)
PI=20〜40%未満 : ○(抑制効果を認める)
PI=40〜60%未満 : △(わずかに抑制効果を認める)
PI=60%以上 : ×(抑制効果を認めない)
【0032】
表1に示したとおり、グリセリン、キシリトール、ソルビトールを加えた試験管には、明らかな白い沈殿が認められ、エリスリトールを加えた試験管にのみ沈殿がまったく生じず、透明であった。これは、エリスリトールによって、ポルフィロモナス・ジンジバリス(porphyromonas gingivalis)、アクチノマイセス・ビスコサス(Actinomices viscoccus)、フゾバクテリウム・ヌクレタム(Fusobacterium nucleatum)の3種の口腔細菌に対する共凝集が抑制されたことを意味するものであり、すなわち、エリスリトールによる口腔細菌の共凝集抑制効果が認められた。
【0033】
表3の結果から、アルギン酸ナトリウムを添加した試験溶液D、E、F、G、Hにおいて、エリスリトールの残留性が向上することを認めた。また、アルギン酸ナトリウムとエリスリトールの配合比(質量比)が50:1〜250:1に調製された試験溶液D、E、Gでは、エリスリトールの残留性がさらに向上し、特に、アルギン酸ナトリウムとエリスリトールの配合比(質量比)が100:1〜200:1に調製された試験溶液Dでは、最も高いエリスリトールの残留性を認めた。
【0034】
Figure 0004852223
【0035】
Figure 0004852223
【0036】
Figure 0004852223
【0037】
Figure 0004852223
【0038】
Figure 0004852223
【0039】
Figure 0004852223
【0040】
Figure 0004852223
【0041】
Figure 0004852223
【0042】
Figure 0004852223
【0043】
Figure 0004852223
【0044】
Figure 0004852223
【0045】
Figure 0004852223
【0046】
Figure 0004852223
【0047】
Figure 0004852223
【0048】
Figure 0004852223
【0049】
Figure 0004852223
【0050】
【表4】
Figure 0004852223
【0051】
表4に本発明に係るエリスリトール、アミノ酸、アルギン酸ナトリウム等が配合されている各種口腔用組成物等の歯垢の形成の抑制効果を示した。表4に示したように、実施例1の練り歯磨きでは、エリスリトールが配合されているため、歯垢の形成抑制効果が認められた。アミノ酸、アルギン酸ナトリウムをさらに含む実施例2〜4の練り歯磨きでは、極めて高い歯垢の形成抑制効果が認められた。また、実施例5の液状歯磨き、実施例6の洗口液、実施例7のキャンディー、実施例8のチューインガムでは、エリスリトール、アミノ酸、アルギン酸ナトリウムが配合されているため、極めて高い歯垢の形成抑制を認めた。
【0052】
一方、エリスリトール、アルギン酸ナトリウムを配合せず、アミノ酸のみを配合した比較例1の練り歯磨き、また、エリスリトール、アミノ酸を配合せず、アルギン酸ナトリウムのみを配合した比較例2の練り歯磨き、さらには、エリスリトール、アミノ酸、アルギン酸ナトリウムが配合されていない比較例3〜8の練り歯磨き、液状歯磨き、洗口液、キャンディー、チューインガムでは、歯垢の形成抑制効果は認められなかった。
【0053】
【発明の効果】
本発明に係るエリスリトールを含む口腔細菌共凝集抑制剤を口腔に適用することによって、口内細菌の共凝集が抑制され、歯垢の形成を効果的に抑制することが可能である。歯垢の形成の抑制により、虫歯、歯周病の予防を図ることができる。[0001]
BACKGROUND OF THE INVENTION
The present invention relates to an oral bacterial coaggregation inhibitor, an oral composition, and the like that suppresses coaggregation of oral bacteria related to the formation of plaque and is excellent in the effect of preventing dental caries and periodontal disease.
[0002]
[Prior art]
Plaque is a sticky bacterial mass attached to the tooth surface. The formation of plaque begins with the formation of a pellicle (acquired film) composed of saliva components on the tooth surface. The pellicle is an amorphous film-like structure formed on the tooth surface, and saliva components such as glycoproteins and polypeptides are selectively adsorbed on the tooth surface. Next, bacteria such as Actinomyces viscosus adhere to the surface of the pellicle, and various bacteria attach through the attached bacteria, and these bacteria propagate to form plaque. Is done.
[0003]
The adhesion between these bacteria is called co-aggregation, and it is said that this co-aggregation makes it possible for bacteria that do not have a strong binding force to the pellicle to settle in plaque. For example, streptococcus mutans and porphyromonas gingivalis, which are the cause of dental caries and periodontal disease, do not directly bind to the pellicle, but this coaggregation causes colonization and induces dental caries and periodontal disease. It is supposed to be one of
[0004]
The plaque thus formed thickens and deposits between the teeth and at the boundary between the teeth and the gingiva. In plaque, there are acids and toxins produced by bacteria, enzymes that destroy tissues, and the like, which is one of the main causes of dental caries, gingivitis, periodontitis and the like. Therefore, suppression of plaque formation and complete removal of already formed plaque are very effective means for preventing and treating dental caries and preventing and treating periodontal diseases.
[0005]
As a means for suppressing the formation of such plaque, bactericides have been widely used. However, when this bactericidal agent is applied to the oral cavity, it is necessary to consider not only the bactericidal effect of oral bacteria but also the influence on the oral mucosa, so the blending concentration must be lowered. Such a blending concentration was never sufficient for suppressing the formation of plaque.
[0006]
In addition, a method of brushing the plaque that has been formed by brushing with a toothpaste containing an abrasive is also widely used, but it is difficult to completely remove plaque by brushing alone, and the plaque that has been left unpolished, Causes decay, gingivitis, and periodontitis. Therefore, it can be said that the effect of preventing dental caries and periodontal disease is still insufficient only by removing plaque using conventional means.
[0007]
On the other hand, erythritol is one kind of sugar alcohol mainly used for food sweeteners. In Patent Document 1, despite the presence of normal palpable sweeteners by replacing erythritol's antidepressive properties, that is, by replacing a part of the existing palatable sweeteners with erythritol. It is disclosed that it does not involve the production of excess acid. This is because erythritol is not fermented by bacteria in the mouth, especially streptococci, that is, the bacterium itself cannot metabolize erythritol, so it does not produce lactic acid that causes dental caries and also forms plaque. This is because it does not produce water-insoluble glucan.
[0008]
In order to prevent colonization and propagation of pathogenic bacteria that cause dental caries and periodontal disease, it is effective to suppress coaggregation of bacteria and bacteria. Patent Document 2 discloses an oral hygiene composition containing an amino sugar as an anti-plaque agent, and amino sugars such as N-heptylgalactosylamine, N-heptyllactosylamine, and N-decyllactosylamine are bacterial aggregates. It is disclosed to exhibit inhibitory activity. However, these amino sugars have a problem that the storage stability in the composition is poor and the cost is high.
[0009]
[Patent Document 1]
JP-A-10-33138 [Patent Document 2]
Japanese Patent Laid-Open No. 6-24948
[Problems to be solved by the invention]
The object of the present invention is to suppress oral bacterial coaggregation to suppress dental plaque causing causative teeth and periodontal disease, and to prevent oral bacterial coaggregation excellent in preventing dental caries and periodontal disease The purpose is to provide.
[0011]
[Means for Solving the Problems]
The present invention is a coaggregation inhibitor of periodontal disease-causing bacteria containing erythritol. By applying the coaggregation inhibitor for periodontal disease-causing bacteria according to the present invention to the oral cavity, it is possible to effectively inhibit the coaggregation of periodontal disease-causing bacteria.
[0012]
Coaggregation of oral bacteria involves specific adhesins specific to bacterial species and binding receptors, and it is considered that coaggregation occurs only between specific bacterial species. Although the mechanism by which erythritol effectively suppresses coaggregation of oral bacteria has not yet been clarified, before erythritol acts on a receptor that causes coaggregation of bacteria and bacteria, It is presumed that it was possible to prevent coaggregation.
[0013]
DETAILED DESCRIPTION OF THE INVENTION
Here, as the structure of erythritol, there are three isomers of L-erythritol, D-erythritol, and meso-erythritol, and the present invention may have any of these structures. As the erythritol used in the present invention, those produced by fermenting glucose are mainly used, and those manufactured by Nikken Chemical Co., Ltd., Mitsubishi Chemical Foods Co., Ltd., etc. can be used.
[0014]
The blending amount of erythritol is 0.1 to 80% by mass, preferably 1 to 60% by mass, particularly 10 to 50% by mass, from the viewpoint of sufficient coaggregation inhibitory effect of oral bacteria and storage stability. It is preferable.
[0015]
In addition to the above-mentioned components, the oral composition of the present invention includes, for example, foaming agents, foaming aids, abrasives, wetting agents, binders, bulking agents, sweeteners, preservatives, bactericides, medicinal ingredients, and adhesives. , Pigments, dyes, fragrances and the like can be appropriately contained.
The composition for oral cavity of the present invention can be prepared in a dosage form such as a solution, gel, or paste. In addition, the coaggregation inhibitor according to the present invention can be used for oral compositions such as dentifrices, liquid dentifrices, mouthwashes, etc., or can be used for candy and chewing gum.
[0016]
Moreover, the coaggregation inhibitory effect of oral bacteria can be enhanced by further using an amino acid in combination with the product of the present invention containing erythritol. This is because, like erythritol, erythritol was able to block bacterial coaggregation by acting on a receptor that causes bacterial coagulation of bacteria before bacterial coagulation of bacteria. It is estimated.
[0017]
The amino acids here are preferably basic amino acids such as lysine, arginine, histidine, tryptophan, proline, oxyproline, and more preferably lysine and arginine from the viewpoint of cost and storage stability.
[0018]
The compounding amount of the amino acid is 0.01 to 10% by mass, preferably 0.05 to 5% by mass, particularly 0.1 to 2%, from the viewpoint of sufficient coaggregation suppressing effect of oral bacteria and storage stability. It is preferable that it is mass%.
[0019]
Moreover, the residual property of erythritol in the oral cavity can be enhanced by further using sodium alginate in combination with erythritol or the product of the present invention containing erythritol and an amino acid. This is presumed to be due to the property that sodium alginate reacts with calcium ions to form a gel. Erythritol is easily taken up into the generated calcium alginate gel, and further, the gel adsorbs to the teeth and mucous membranes, so that the persistence in the oral cavity is increased. Estimated to be supplied from the liquid.
[0020]
In this case, the blending ratio (mass ratio) of erythritol and sodium alginate is preferably 50: 1 to 250: 1, particularly 100: 1 to 200: 1.
Sodium alginate here is not affected by the ratio of manuronic acid and guluronic acid constituting alginic acid, but is commercially available from Kimika Co., Ltd., Dainippon Pharmaceutical Co., Ltd. Those having a guluronic acid (M / G ratio) of 0.5 to 2.5 can be used.
[0021]
【Example】
EXAMPLES Hereinafter, although an experiment example and an Example are shown and this invention is demonstrated more concretely, these things do not limit the scope of the present invention.
[0022]
<Example A> Coaggregation inhibitory effect of oral bacteria Three types of oral bacteria (approximately 10 each) of Porphyromonas gingivalis, Actinomyces viscoccus, and Fusobacterium nucleatum 6 ) were added to the test tube, and 20 ml of physiological saline was added to sufficiently disperse the bacteria. Furthermore, glycerol, erythritol, xylitol, and sorbitol were added to the test tubes in which the bacteria were sufficiently dispersed, respectively, so that the concentration of the aqueous solution was 1.0% by mass. This aqueous solution was allowed to stand at 4 ° C., and the presence or absence of precipitation of the solution after standing for 30 minutes was visually observed. The results are shown in Table 1.
[0023]
[Table 1]
Figure 0004852223
[0024]
<Judgment criteria>
No white precipitate is observed: ○
Slightly white precipitate is observed: △
A clear white precipitate is recognized: ×
[0025]
<Example B> Hydroxyapatite pellets (manufactured by Asahi Kogyo Co., Ltd., 10 mm × 10 mm, hereinafter referred to as HAP) are added to the soup collected from the residual human in the oral cavity of erythritol, and stirred at 37 ° C. for 1 hour. A saliva coat HAP was prepared. The saliva-coated HAP was immersed in the test solutions A, B, C, D, E, F, G, and H shown in Table 2 and stirred for 2 minutes, and then the saliva-coated HAP was taken out. To this, 2 ml of a mixed solution of acetonitrile / water (80/20) was added and stirred sufficiently, followed by filtration with a 0.45 μm Millipore filter. The filtrate was subjected to liquid chromatographic analysis under the following conditions to quantify erythritol. The results are shown in Table 3.
[0026]
[Table 2]
Figure 0004852223
[0027]
[Table 3]
Figure 0004852223
[0028]
<Conditions>
Analysis column: TSK-GEL Amido-80 manufactured by Tosoh Corporation (4.6 mm x 250 mm)
Eluent: acetonitrile / water (80/20)
Flow rate: 1 mL / min Column temperature: 40 ° C
Detector: Differential refractometer injection amount: 20 μL
[0029]
<Example C> Plaque formation inhibitory effect Dental plaques by dental hygienists completely removed the plaques of 10 subjects, and then the subjects removed the compositions shown in the examples below for 2 weeks each. used. Thereafter, the use of the composition shown in the Examples for 24 hours was stopped, and after 24 hours, a dental hygienist measured the amount of plaque formed using Silness and Loe's PI (Plaque Index). The results are shown in Table 4. However, the result was shown by the average value of 10 subjects. Moreover, the composition shown in the Example was used with the following method.
[0030]
<How to use>
1. Toothpaste, liquid toothpaste: About 1 g of toothpaste was applied to a toothbrush, brushed for about 2 minutes, and used 3 times a day.
2. Mouthwash: About 10 ml of mouthwash was contained in the mouth and rinsed for about 30 seconds. After each meal, it was used between meals and 6 times a day.
3. Candy: About 5 g of candy was included in the mouth and licked without chewing. After each meal, it was used between meals and 6 times a day.
4). Chewing gum: About 3 g of chewing gum was included in the mouth and chewed for about 10 minutes. After each meal, it was used between meals and 6 times a day.
[0031]
<Judgment criteria>
PI = 0 to less than 20%: ◎ (high suppression effect is recognized)
PI = 20 to less than 40%: ○ (inhibiting effect is recognized)
PI = 40 to less than 60%: Δ (slightly suppressive effect)
PI = 60% or more: × (no inhibitory effect)
[0032]
As shown in Table 1, a clear white precipitate was observed in the test tube to which glycerin, xylitol, and sorbitol were added, and only a test tube to which erythritol was added had no precipitate at all and was transparent. This means that erythritol inhibited co-aggregation of three types of oral bacteria: porphyromonas gingivalis, Actinomyces viscoccus, and Fusobacterium nucleatum. That is, an effect of inhibiting coaggregation of oral bacteria by erythritol was observed.
[0033]
From the results in Table 3, it was confirmed that the residual properties of erythritol were improved in the test solutions D, E, F, G, and H to which sodium alginate was added. In addition, in the test solutions D, E, and G prepared with a blending ratio (mass ratio) of sodium alginate and erythritol of 50: 1 to 250: 1, the residual properties of erythritol are further improved. In particular, sodium alginate and erythritol In the test solution D prepared at a blending ratio (mass ratio) of 100: 1 to 200: 1, the highest residual erythritol was observed.
[0034]
Figure 0004852223
[0035]
Figure 0004852223
[0036]
Figure 0004852223
[0037]
Figure 0004852223
[0038]
Figure 0004852223
[0039]
Figure 0004852223
[0040]
Figure 0004852223
[0041]
Figure 0004852223
[0042]
Figure 0004852223
[0043]
Figure 0004852223
[0044]
Figure 0004852223
[0045]
Figure 0004852223
[0046]
Figure 0004852223
[0047]
Figure 0004852223
[0048]
Figure 0004852223
[0049]
Figure 0004852223
[0050]
[Table 4]
Figure 0004852223
[0051]
Table 4 shows the effect of suppressing the formation of plaque in various oral compositions containing erythritol, amino acids, sodium alginate and the like according to the present invention. As shown in Table 4, since the toothpaste of Example 1 contains erythritol, an effect of suppressing the formation of plaque was observed. In the toothpastes of Examples 2 to 4 further containing an amino acid and sodium alginate, an extremely high plaque formation inhibitory effect was observed. In addition, the liquid toothpaste of Example 5, the mouthwash of Example 6, the candy of Example 7, and the chewing gum of Example 8 contain erythritol, amino acids, and sodium alginate, and therefore extremely high suppression of plaque formation. Admitted.
[0052]
On the other hand, the toothpaste of Comparative Example 1 in which erythritol and sodium alginate were not blended and only amino acids were blended, and the toothpaste of Comparative Example 2 in which only erythritol and amino acids were blended but only sodium alginate was blended, and further erythritol In the toothpaste, liquid toothpaste, mouthwash, candy, and chewing gum of Comparative Examples 3 to 8 in which no amino acid or sodium alginate was blended, no plaque formation inhibitory effect was observed.
[0053]
【The invention's effect】
By applying the oral bacterial coaggregation inhibitor containing erythritol according to the present invention to the oral cavity, coaggregation of oral bacteria can be suppressed, and plaque formation can be effectively suppressed. Prevention of dental caries and periodontal disease can be achieved by suppressing the formation of plaque.

Claims (4)

エリスリトールを有効成分とする歯周病原因細菌の共凝集抑制剤。A coaggregation inhibitor of periodontal disease-causing bacteria containing erythritol as an active ingredient . エリスリトールを1〜80質量%含有する請求項1に記載の歯周病原因細菌の共凝集抑制剤。  The coaggregation inhibitor of periodontal disease-causing bacteria according to claim 1, comprising 1 to 80% by mass of erythritol. アルギン酸ナトリウムをさらに含む請求項1又は2に記載の歯周病原因細菌の共凝集抑制剤。  The coaggregation inhibitor of periodontal disease-causing bacteria according to claim 1 or 2, further comprising sodium alginate. エリスリトール対アルギン酸ナトリウムの配合比(質量比)が50:1〜250:1である請求項3に記載の歯周病原因細菌の共凝集抑制剤。  The coaggregation inhibitor of periodontal disease-causing bacteria according to claim 3, wherein the blending ratio (mass ratio) of erythritol to sodium alginate is 50: 1 to 250: 1.
JP2003175914A 2003-06-20 2003-06-20 Coaggregation inhibitor of oral bacteria Expired - Lifetime JP4852223B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2003175914A JP4852223B2 (en) 2003-06-20 2003-06-20 Coaggregation inhibitor of oral bacteria

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2003175914A JP4852223B2 (en) 2003-06-20 2003-06-20 Coaggregation inhibitor of oral bacteria

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2006326838A Division JP4709735B2 (en) 2006-12-04 2006-12-04 Coaggregation inhibitor of oral bacteria

Publications (2)

Publication Number Publication Date
JP2005008579A JP2005008579A (en) 2005-01-13
JP4852223B2 true JP4852223B2 (en) 2012-01-11

Family

ID=34098929

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003175914A Expired - Lifetime JP4852223B2 (en) 2003-06-20 2003-06-20 Coaggregation inhibitor of oral bacteria

Country Status (1)

Country Link
JP (1) JP4852223B2 (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006199661A (en) * 2005-01-24 2006-08-03 Sunstar Inc Coaggregation inhibitor
JP2007063187A (en) * 2005-08-31 2007-03-15 Kao Corp Dentifrice composition
JP4641231B2 (en) * 2005-08-31 2011-03-02 花王株式会社 Toothpaste composition
US8961938B2 (en) 2005-09-05 2015-02-24 Kao Corporation Dentifrice composition
JP4719537B2 (en) * 2005-09-05 2011-07-06 花王株式会社 Toothpaste composition
JP2007070261A (en) * 2005-09-05 2007-03-22 Kao Corp Dentifrice composition
JP5006567B2 (en) * 2006-04-14 2012-08-22 花王株式会社 Oral solid formulation
JP4849980B2 (en) * 2006-07-12 2012-01-11 花王株式会社 Toothpaste composition
JP4709735B2 (en) * 2006-12-04 2011-06-22 花王株式会社 Coaggregation inhibitor of oral bacteria
JP5202895B2 (en) * 2007-07-20 2013-06-05 花王株式会社 Toothpaste composition
WO2009099454A1 (en) 2008-02-08 2009-08-13 Colgate-Palmolive Company Oral care product and methods of use and manufacture thereof
JP5563226B2 (en) * 2008-11-19 2014-07-30 花王株式会社 Composition for removing solid product formed on tooth surface
WO2010058522A1 (en) * 2008-11-19 2010-05-27 花王株式会社 Method for removing solid product formed on surfaces of teeth
JP5563212B2 (en) * 2008-11-19 2014-07-30 花王株式会社 Oral composition
CN102215813B (en) 2008-11-19 2014-01-08 花王株式会社 Method for removing solid product formed on surfaces of teeth

Also Published As

Publication number Publication date
JP2005008579A (en) 2005-01-13

Similar Documents

Publication Publication Date Title
JP4852223B2 (en) Coaggregation inhibitor of oral bacteria
US4096241A (en) Tooth preparations
KR101992927B1 (en) Toothpaste composition for prevention and improvement of periodontal disease
CA2882558C (en) Mineral-enzyme complex for strengthening and whitening tooth enamel, oral hygiene composition, and toothpaste
JPH08502970A (en) Antibacterial mouthwash
RU2293551C1 (en) Composition for mouth cavity disease prophylaxis
JP5825532B2 (en) Tobacco tar remover and compositions based thereon
KR20140082504A (en) Dental composition for a foul smell removal, antiplaque and excellent anti-microbial effect
WO2005072691A1 (en) Composition for inhibiting halitosis
JP4709735B2 (en) Coaggregation inhibitor of oral bacteria
JP3783762B2 (en) Stain removal oral composition
JPS5811924B2 (en) Oral composition
WO2013192630A1 (en) Foaming oral care formulation and system and method of forming and using same
JPS5811927B2 (en) Oral composition
JP2726490B2 (en) Oral composition
FR2838339A1 (en) Polyphosphonate derivatives useful in toothpastes, mouthwashes, chewing gums and the like for the prevention of dental plaque and caries
JPH10236934A (en) Oral composition
JP2000229823A (en) Composition for oral cavity
JP2546263B2 (en) Bad breath remover
JP3065947B2 (en) Oral composition
JP2002193776A (en) Cleaning agent for oral cavity
JP2002338457A (en) Prophylactic/therapeutic agent for periodontosis
KR900005069B1 (en) Tooth paste compositions
JP2001278763A (en) Cariostatic agent
JPS61130212A (en) Composition for oral cavity

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20050803

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20060929

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20061003

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20061204

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20061206

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20080311

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080422

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20080624

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080825

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20081007

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090908

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20091109

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20100305

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20111024

R151 Written notification of patent or utility model registration

Ref document number: 4852223

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R151

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20141028

Year of fee payment: 3

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

EXPY Cancellation because of completion of term